A year and a half after exceeding expectations with its $238 million IPO, Graphite Bio has hit a major roadblock as an adverse event caused the gene-therapy-focused biotech to pause its lead program.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,